Long-term effects of dalfampridine in patients with multiple sclerosis

Dalfampridine is the extended-release formulation of 4-aminopyridine and is approved for the symptomatic treatment of impaired mobility in patients with multiple sclerosis. Our aim was to examine the short- and long-term effects of treatment with dalfampridine on motoric and cognitive assessment par...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of the neurological sciences Ročník 337; číslo 1-2; s. 18 - 24
Hlavní autoři:	Ruck, T., Bittner, S., Simon, O.J., Göbel, K., Wiendl, H., Schilling, M., Meuth, S.G.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Netherlands Elsevier B.V 15.02.2014
Témata:	4-Aminopyridine - therapeutic use Cognition Disorders - drug therapy Cognition Disorders - etiology Dalfampridine Disability Evaluation Drug Delivery Systems Electroencephalography Evoked Potentials - drug effects Evoked Potentials - physiology Fatigue Female Follow-Up Studies Humans Long-term treatment Male Middle Aged Mobility Multiple Sclerosis - complications Multiple Sclerosis - drug therapy Neurology Potassium Channel Blockers - therapeutic use Severity of Illness Index Statistics, Nonparametric Time Factors Walking - physiology Walking ability Mobility Fatigue Dalfampridine Long-term treatment MS Walking ability
ISSN:	0022-510X, 1878-5883, 1878-5883
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!